David Ringel
Family Medicine · Centennial, CONPI 1457889859
Payments from drug & device makers
Across 95 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceutical Holding Company Ltd.$444
- AbbVie$324
- Amgen$275
- Lilly USA, LLC$180
- Novo Nordisk$145
- Merck$90
- plus $496 from 17 others
What the payments were for
- Food & beverage$1,88697%
- Education$683%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | 17 | $444 |
| AbbVie | 12 | $324 |
| Amgen | 15 | $275 |
| Lilly USA, LLC | 13 | $180 |
| Novo Nordisk | 8 | $145 |
| Merck | 6 | $90 |
| Sanofi Pasteur Inc. | 1 | $68 |
| Eisai Inc. | 3 | $52 |
| GSK | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| AstraZeneca | 3 | $41 |
| E.r. Squibb & Sons, L.L.C. | 1 | $29 |
| Boehringer Ingelheim | 1 | $25 |
| Kowa Pharmaceuticals America, Inc. | 1 | $24 |
| Exeltis, USA Inc. | 1 | $24 |
| Corium, LLC | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| Lucid Diagnostics Inc. | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Cranial Technologies, Inc | 1 | $13 |
How this compares
$1,954 in reported general payments places this provider in the 85th percentile of 2,079 family medicine providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $20,162 |
| JardianceEmpagliflozin | 38 | $18,003 |
| PradaxaDabigatran Etexilate Mesylate | 42 | $12,216 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 38 | $5,586 |
| Levothyroxine Sodium | 266 | $4,649 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 20 | $4,000 |
| Wixela InhubFluticasone Propion/Salmeterol | 15 | $3,843 |
| Atorvastatin Calcium | 295 | $3,487 |
| AlvescoCiclesonide | 12 | $2,074 |
| Lisinopril | 169 | $1,904 |
| Humulin NInsulin Nph Human Isophane | 11 | $1,807 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 43 | $1,691 |
| Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm | 12 | $1,638 |
| Amlodipine Besylate | 131 | $1,517 |
| Omeprazole | 101 | $1,504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Pradaxa | $25 | $30,21980 claims |
| GSKArexvy, Shingrix | $48 | $9,58658 claims |
| Lilly USA, LLCHumulin N | $180 | $1,80711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Centennial
- Liberty Amador BarryCentennial$30K
- Clint FlanaganDacono$7.6M
- Larry OdekirkCastle Rock$6.3M
- Ripley HollisterColorado Springs$5.5M
- Timothy ColanderAurora$3.1M
- Mia ScottDenver$993K
- Matthew LewisAurora$960K
- Ethan LazarusDenver$688K
- Patrick BarryFraser$568K
- Astrid LampeyFraser$568K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.